IPO Weekly Recap: Akcea Therapeutics cuts valuation, trades well in debut
This past week two IPOs came to market which included a hold-over from June, Akcea Therapeutics (Nasdaq: AKCA). Akcea Therapeutics (Nasdaq: AKCA) reworked the terms of its offering and was welcomed to the public market with a strong debut. AKCA priced 15.6mm shares at $8.00 a rather large share increase from the 9.6mm shares filed and[…]
